Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global rights to US firm PhaseBio Pharmaceuticals Inc.’s pre-clinical drug candidate PB6440. This strategic partnership aims to advance the development of a next-generation aldosterone synthetase inhibitor (ASi) with significant potential in treating cardiovascular, renal, and metabolic diseases.
PB6440: Next-Generation ASi
PB6440 is a new generation, highly selective aldosterone synthetase inhibitor (ASi). Aldosterone plays a crucial role in regulating blood pressure and electrolyte balance. Mineralocorticoid receptor antagonists or aldosterone antagonists have been proven effective in treating many cardiovascular, renal, and metabolic diseases. Preclinical studies have shown that PB6440 can effectively inhibit aldosterone synthetase with minimal interaction with homologous enzymes in the body, reducing the inhibitor’s impact on the cortisol pathway. Currently, there is no similar product approved anywhere in the world.
Global Rights and Development Potential
By obtaining global rights to PB6440, Ji Xing Pharmaceuticals aims to leverage its expertise and resources to accelerate the drug’s development and bring it to market. This move underscores Ji Xing’s commitment to innovation and expanding its portfolio of advanced therapeutic solutions.-Fineline Info & Tech
